[The thrombophilic status of patients with inflammatory diseases].
OBJECTIVE
Inflammatory reactions are taken to be nonspecific defensive measures of the organism and are associated with complex changes at cellular and humoral level. Activation of blood coagulation plays an important part in this, especially as it is accompanied by an increased risk of thromboembolism. It was the aim of this investigation to assess this risk by measuring sensitive markers of coagulation activation.


METHODS
Biochemical markers of coagulation activation (prothrombin-fragment F1 + 2 and thrombin-antithrombin III complex [TAT]) and fibrin formation (D-dimer) were measured in 130 patients (61 men, 69 women; mean age 56.9 [20-89] years). 44 had pneumonia, 44 bronchitis and 42 urinary tract infections. A healthy control group for comparison consisted of 11 men and 15 women (mean age 48.7 [23-79] years).


RESULTS
F1 + 2, TAT and D-dimer were significantly increased, compared with the controls, in all three patient groups (P < 0.01). The greatest rises occurred in the patients with pneumonia: F1 + 2: median 1.2 vs 0.6 nmol/I, TAT: 6.2 vs 2.1 micrograms/l and D-dimer 2476 vs 223 ng/ml.


CONCLUSIONS
These findings underline the importance of consistent thrombosis prophylaxis in patients with inflammatory disease, especially those at an increased risk.
Lins
M
M
I. Medizinische Klinik, Universität Kiel.
Zurborn
K H
KH
Pries
B
B
Bruhn
H D
HD
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001780:Blood Coagulation Tests / Q000706:statistics & numerical data; D001991:Bronchitis / Q000097:blood / Q000150:complications*; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000097:blood / Q000150:complications*; D011446:Prospective Studies; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood / Q000209:etiology*; D014552:Urinary Tract Infections / Q000097:blood / Q000150:complications*
D015415:Biomarkers; D002097:C-Reactive Protein
Thrombophiler Status bei Patienten mit entzündlichen Erkrankungen.